Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints

Off-label Marketing

Although the pharmaceutical business is a major force in the advancement of healthcare, questions continue to be raised about the moral limits of medication marketing strategies, especially when it comes to off-label promotion. This review study sheds light on the tactics and procedures used in pharmaceutical off-label marketing by undertaking a thorough retrospective analysis of whistleblower allegations. We investigate the many facets of off-label promotion, looking at the techniques, goals, and outcomes by combining data from industry practises, legal cases, and regulatory actions. Apart from analysing the adverse effects linked to off-label marketing, this assessment pinpoints possible domains for enhancement in regulatory structures and enforcement protocols. Our objective is to offer valuable insights that can guide the formulation of future policies and industry practises by critically evaluating past cases. In the end, this research adds to the continuing conversation on the moral issues raised by pharmaceutical marketing and the necessity of finding a balance between patient welfare, innovation, and regulatory compliance in the rapidly changing healthcare environment.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.